Incyte (INCY) · axatilimab + ruxolitinib
Earlier window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: early 2027
ruxolitinib in patients with newly diagnosed chronic GVHD is ongoing, with results anticipated in early 2027
· filed · SEC filing
After
Stated timing: second half of 2026
Data from the Phase 2 trial evaluating axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic GVHD are anticipated in the second half of 2026
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/INCY-axatilimab-ruxolitinib-2026-04-28, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/INCY-axatilimab-ruxolitinib-2026-04-28
Incyte (INCY) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.